IMR Press / FBE / Volume 2 / Issue 2 / DOI: 10.2741/E101

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Expression of VEGF, VEGF-C and VEGFR-2 in in situ and invasive SCC of cervix

Show Less
1 Chair of Gynecology and Obstetrics, Department of Gynecology, Obstetrics and Oncology
2 Medical Biochemistry, Jagiellonian University, Medical College, Krakow, Poland

*Author to whom correspondence should be addressed.

Front. Biosci. (Elite Ed) 2010, 2(2), 411–423;
Published: 1 January 2010

Cervical squamous cell carcinoma (SCC) arises from the metaplastic epithelium and develops slowly through dysplastic changes (i.e., cervical intraepithelial neoplasia - CIN) to carcinoma in situ and invasive cancer. There is little data concerning the quantitation of vascular endothelial growth factor (VEGF) and its correlation to the clinical or pathologic characteristics of SCC. This study assessed the expression of VEGF, VEGF-C and their receptor VEGFR-2 in 35 samples of normal cervical tissue, 35 - CIN1, 35 - CIN2 (25 non-pregnant, 15 pregnant women), 35 - CIN3 and 30- SCC. VEGF, VEGF-C and VEGFR-2 were analyzed using RT-PCR, RQ-PCR, immunohistochemical staining and Western blot. VEGF, VEGF-C and VEGFR-2 were not detected in normal cervical epithelium. In CIN and SCC, both forms of VEGF and its receptor were identified, indicating a correlation between the increasing expression and staging of carcinoma. Results show the important role of VEGF in cervical progression and that the switch to the lymphangiogenesis phenotype occurs prior to the stage of invasion likely at CIN2/3.

Cervical cancer
Vascular Endothelial Growth Factor
Back to top